The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Abstract
BACKGROUND: It is believed that BRCA1 and BRCA2 germline mutations account for the majority of hereditary ovarian carcinomas; however, to the authors' knowledge, there are scant data on the prevalence and spectrum of mutations, genotype/phenotype correlations, tumor histology, and family history characteristics. To address this gap, the authors conducted a population‐based study of 232 incident epithelial ovarian carcinomas in the Tampa Bay area. METHODS: Genetic testing for the BRCA1 and BRCA2 genes was performed through full sequencing and BRCA1 rearrangement testing. RESULTS: Of 209 women with invasive ovarian carcinoma, 32 women (15.3%) had mutations in BRCA1 or BRCA2, including 20 BRCA1 mutations and 12 BRCA2 mutations. Of the BRCA2 mutations, 58% were outside the “ovarian cancer cluster region” (OCCR). Variants of uncertain significance were detected in 8.2% of women with invasive ovarian carcinoma. No mutations were identified in women with borderline or invasive mucinous tumors. Among the BRCA mutation‐positive women, 63% had serous tumors. A family history of breast and/or ovarian carcinoma was reported in 65%, 75%, and 43.5% of relatives of BRCA1 carriers, BRCA2 carriers, and non‐BRCA1/BRCA2 carriers, respectively. CONCLUSIONS: The data from this study suggested that 1) previous studies may have underestimated the frequency of BRCA1 and BRCA2 mutations in ovarian carcinomas, especially outside the OCCR; 2) it may be reasonable to offer genetic counseling to any woman with an invasive, nonmucinous epithelial ovarian tumor; and 3) among patients with invasive ovarian carcinoma, family history is not sufficiently accurate to predict mutation status. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
WHO handbook for reporting results of cancer treatment
Sylvester, R. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90009-4 · Cited by 1,055
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Principles and Practice of Gynecologic Oncology
Moore, W. (1997) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199707000-00022 · Cited by 838
Frank, T. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1480 · Cited by 812
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Clinicopathologic Features of <EMPH TYPE="ITAL">BRCA</EMPH>-Linked and Sporadic Ovarian Cancer
Boyd, J. (2000) · JAMA · doi:10.1001/jama.283.17.2260 · Cited by 536
Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2417 · Cited by 455
Improved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., Eijk, R. V., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Metadata
- Authors
- Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., Wilbanks, G., Nicosia, S., Cantor, A., & Sutphen, R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-11-14
- Volume
- 104
- Issue
- 12
- Pages
- 2807-2816
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1484356204
- Cited by
- 691
- References
- 33
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. https://app.cochat.ai/papers/10.1002/cncr.21536
- The paper
- Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., Wilbanks, G., Nicosia, S., Cantor, A., & Sutphen, R. (2005). BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. https://doi.org/10.1002/cncr.21536
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.